The Different Immunoregulatory Functions of Mesenchymal Stem Cells in Patients with Low-Risk or High-Risk Myelodysplastic Syndromes

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Zhao, Zhigang ^a   Wang, Zhenling ^a   Li, Qiubai ^b   Li, Weiming ^b   You, Yong ^b   Zou, Ping ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; APOPTOSIS; ARTICLE; BONE MARROW; CELL ISOLATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOREGULATION; LOW RISK POPULATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MIXED LYMPHOCYTE REACTION; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HUMANS; LYMPHOCYTE CULTURE TEST, MIXED; MESENCHYMAL STROMAL CELLS; MYELODYSPLASTIC SYNDROMES; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84866707729     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045675     Document Type: Article

References (34)

1. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ, (2001) Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 25: 1075-1083.
2. Wlodarski MW, O'Keefe C, Howe EC, Risitano AM, Rodriguez A, et al. (2005) Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood 106: 2769-2780.
3. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ, (2003) A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102: 3025-3027.
4. AsanoY, Maeda M, Uchida N, Yokoyama T, Osaki K, et al. (2001) Immunosuppressive therapy for patients with refractory anemia. Ann Hematol 80: 634-638.
5. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, et al. (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23: 7594-7603.
6. Aggarwal S, van de Loosdrecht AA, Alhan C, Ossenkoppele GJ, Westers TM, et al. (2011) Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol 153: 568-581.
7. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC, (2003) Suppression of allogeneic T-cell proliferation by human marrow stromal cells:Implications in transplantation, Transplantation. 75: 389-397.
8. Aggarwal S, Pittenger MF, (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815-1822.
9. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, et al. (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101: 3722-3729.
10. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, et al. (2005) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105: 4120-4126.
11. Zhao ZG, Li WM, Chen ZC, You Y, Zou P, (2008) Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patient with hematological malignant diseases. Leukemia & Lymphoma 9: 2187-2195.
12. Guo H, Fang B, Liao L, Zhao Z, Liu J, et al. (2003) Hemangioblastic characteristics of fetal bone marrow-derived Flk1+CD31-CD34-cells. Exp Hematol 31: 650-658.
13. Devine SM, Hoffman R, (2000) Role of mesenchymal stem cells in hematopoietic stem cell transplantation. Curr Opin Hematol 7: 385-363.
14. Sakaguchi S, (2005) Naturally arising Foxp3-expressing CD25+CD4+regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352.
15. Sato K, Yamashita N, Yamashita N, Baba M, Matsuyama T, (2003) Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 18: 367-379.
16. Peng Y, Laouar Y, Li MO, Green EA, Flavell RA, (2004) TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A 101: 4572-4577.
17. Chen W, Jin W, Hardegen N, Lei KJ, Li L, et al. (2003) Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198: 1875-1886.
18. Yamazaki S, Bonito AJ, Spisek R, Dhodapkar M, Inaba K, et al. (2007) Dendritic cells are specialized accessory cells along with TGF- for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3 precursors. Blood 110: 4293-4302.
19. Klaus M, Stavroulaki E, Kastrinaki MC, Fragioudaki P, Giannikou K, et al. (2010) Reserves, functional, immunoregulatory and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev 19: 1043-1054.
20. Han Q, Sun Z, Liu L, Chen B, Cao Y, et al. (2007) Impairment in immuno-modulatory function of Flk1(+)CD31(-)CD34(-) MSCs from MDS-RA patients. Leuk Res 31: 1369-1378.
21. Bacigalupo A, Valle M, Podesta M, Pitto A, Zocchi E, et al. (2005) T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 3: 819-827.
22. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ, (2001) Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 25: 1075-1083.
23. Wlodarski MW, O'Keefe C, Howe EC, Risitano AM, Rodriguez A, et al. (2005) Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood 106: 2769-2780.
24. Wlodarski MW, Gondek LP, Nearman ZP, Plasilova M, Kalaycio M, et al. (2006) Molecular strategies for detection and quantitation of clonal cytotoxic T cell responses in aplastic anemia and myelodysplastic syndrome. Blood 108: 2632-2641.
25. Beyer M, Schultze JL, (2006) Regulatory T cells in cancer. Blood 108: 804-811.
26. Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, et al. (2007) CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).Blood. 110: 847-850.
27. Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, et al. (2010) Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol 184: 5885-5894.
28. Shi Y, Massague J, (2003) Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113: 685-700.
29. Gorelik L, Flavell RA, (2002) Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2: 46-53.
30. Chen W, Wahl SM, (2002) TGF-beta: receptors, signaling pathways and autoimmunity. Curr Dir Autoimmun 2002 5: 62-91.
31. Mantel PY, Schmidt-Weber CB, (2011) Transforming growth factor-beta: recent advances on its role in immune tolerance. Methods Mol Biol 677: 303-338.
32. Buck MB, Knabbe C, (2006) TGF-beta signaling in breast cancer.Ann N Y Acad Sci. 1089: 119-126.
33. Zhao ZG, Li WM, Chen ZC, Zou P, (2008) Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patients with chronic myeloid leukemia. Immunological Investigations 37: 726-739.
34. Wang J, Liu K, Lu DP, (2005) Mesenchymal stem cells in stem cell transplant recipients are damaged and remain of host origin. Int J Hematol 82: 152-158.